Boundless Bio, Inc. (BOLD)
Automate Your Wheel Strategy on BOLD
With Tiblio's Option Bot, you can configure your own wheel strategy including BOLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BOLD
- Rev/Share 0.0
- Book/Share 6.1252
- PB 0.1829
- Debt/Equity 0.3556
- CurrentRatio 22.1464
- ROIC -0.3982
- MktCap 25071883.0
- FreeCF/Share -2.7851
- PFCF -0.4037
- PE -0.3802
- Debt/Assets 0.254
- DivYield 0
- ROE -0.4161
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BOLD | H.C. Wainwright | -- | Buy | -- | $5 | June 2, 2025 |
| Downgrade | BOLD | Leerink Partners | Outperform | Market Perform | -- | $3 | May 28, 2025 |
| Downgrade | BOLD | Guggenheim | Buy | Neutral | -- | -- | Dec. 13, 2024 |
News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Read More
New Strong Sell Stocks for May 1st
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
AMPY, ASTS and BOLD have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2025.
Read More
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham's Virtual Healthcare Conference.
Read More
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and …
Read More
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink's Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m.
Read More
About Boundless Bio, Inc. (BOLD)
- IPO Date 2016-07-20
- Website https://boundlessbio.com
- Industry Biotechnology
- CEO Mr. Zachary Hornby
- Employees 64